Vemurafenib
Sign in to save this workspacePrimary targets: BRAF · FDA status: FDA Approved
Selectivity scorecard
KISS
96.49
Gini
0.598
CATDS
0.011
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Vemurafenib. Strongest target: LCK at 98.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | LCK | 98.4% | 1.6% |
| 2 | KHS_MAP4K5 | 98.3% | 1.7% |
| 3 | MEK2 | 98.1% | 1.9% |
| 4 | BRK | 98.0% | 2.0% |
| 5 | ARAF | 96.9% | 3.1% |
| 6 | MYLK4 | 95.8% | 4.2% |
| 7 | SRMS | 95.3% | 4.7% |
| 8 | RAF1 | 95.2% | 4.8% |
| 9 | RIPK3 | 94.5% | 5.5% |
| 10 | MEK5 | 94.4% | 5.6% |
| 11 | TNIK | 94.4% | 5.6% |
| 12 | FGR | 93.6% | 6.4% |
| 13 | ZAK_MLTK | 92.9% | 7.1% |
| 14 | BRAF | 92.8% | 7.2% |
| 15 | MLCK2_MYLK2 | 89.6% | 10.4% |
| 16 | DDR2 | 89.4% | 10.6% |
| 17 | MST1_STK4 | 89.0% | 11.0% |
| 18 | WNK3 | 88.5% | 11.5% |
| 19 | BLK | 87.8% | 12.2% |
| 20 | TGFBR2 | 86.4% | 13.6% |
Selectivity landscape
Where Vemurafenib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Vemurafenib.
Atlas insights for Vemurafenib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target1%
Off-target99%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 3113.85 | |
| ALLOGRAFT_REJECTION | 8338.88 | |
| ANDROGEN_RESPONSE | 1976.28 | |
| ANGIOGENESIS | 1431.24 | |
| APICAL_JUNCTION | 8717.77 | |
| APICAL_SURFACE | 951.15 | |
| APOPTOSIS | 7588.57 | |
| BILE_ACID_METABOLISM | 707.78 | |
| CHOLESTEROL_HOMEOSTASIS | 1162.81 | |
| COAGULATION | 1122.48 | |
| COMPLEMENT | 4945.72 | |
| DNA_REPAIR | 2004.79 | |
| E2F_TARGETS | 5691.73 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 2238.19 | |
| ESTROGEN_RESPONSE_EARLY | 3716.92 | |
| ESTROGEN_RESPONSE_LATE | 3266.41 | |
| FATTY_ACID_METABOLISM | 783.58 | |
| G2M_CHECKPOINT | 6224.94 | |
| GLYCOLYSIS | 2449.82 | |
| HEDGEHOG_SIGNALING | 786.57 | |
| HEME_METABOLISM | 2452.01 | |
| HYPOXIA | 4348.70 | |
| IL2_STAT5_SIGNALING | 3917.71 | |
| IL6_JAK_STAT3_SIGNALING | 5211.98 | |
| INFLAMMATORY_RESPONSE | 5385.20 | |
| INTERFERON_ALPHA_RESPONSE | 1231.05 | |
| INTERFERON_GAMMA_RESPONSE | 6339.84 | |
| KRAS_SIGNALING_DN | 1049.29 | |
| KRAS_SIGNALING_UP | 3394.23 | |
| MITOTIC_SPINDLE | 6662.35 | |
| MTORC1_SIGNALING | 4102.43 | |
| MYC_TARGETS_V1 | 4540.95 | |
| MYC_TARGETS_V2 | 1096.49 | |
| MYOGENESIS | 3187.01 | |
| NOTCH_SIGNALING | 358.58 | |
| OXIDATIVE_PHOSPHORYLATION | 1311.23 | |
| P53_PATHWAY | 4405.97 | |
| PANCREAS_BETA_CELLS | 525.53 | |
| PEROXISOME | 1113.07 | |
| PI3K_AKT_MTOR_SIGNALING | 9004.25 | |
| PROTEIN_SECRETION | 1997.90 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 690.00 | |
| SPERMATOGENESIS | 1820.88 | |
| TGF_BETA_SIGNALING | 2333.54 | |
| TNFA_SIGNALING_VIA_NFKB | 5389.60 | |
| UNFOLDED_PROTEIN_RESPONSE | 1582.89 | |
| UV_RESPONSE_DN | 5469.34 | |
| UV_RESPONSE_UP | 3797.54 | |
| WNT_BETA_CATENIN_SIGNALING | 2149.82 | |
| XENOBIOTIC_METABOLISM | 1677.57 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.863 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.847 |
| SRR23303752 | — | 0.846 |
| SRR12202498 | — | 0.842 |
| aMVAC.P_005_TURBT_S223 | — | 0.840 |
Annotations
Sign in to read and post annotations.
Loading…